Femasys
Update in progressFEMY (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Instruments & Supplies
Femasys Inc. is a biomedical company that develops therapeutic and diagnostic solutions for women’s health in the United States and internationally. Its portfolio includes FemaSeed for intratubal insemination, FemVue for fallopian tube assessment via ultrasound, FemCerv for cervical cancer sampling, FemCath for selective fallopian tube evaluation, FemChec as a contrast-based fallopian tube diagnostic, and FemBloc, a non-surgical permanent birth-control option. Based in Suwanee, Georgia, since 2004.
Company score
- Sentiment
- 0.54
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.45
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.17
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.35
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMs. Kathy Lee-Sepsick M.B.A.
- Founded2004
- Employees51
- Websitefemasys.com
Identifiers
- ISINUS31447E1055
- FIGIBBG004M23R63
- CUSIP31447E105
- CIK0001339005